Tag: KDC-MN-243

  • Lamotrigine

    Phenyltriazine sodium channel blocker / mood stabilizer

    A phenyltriazine voltage-gated sodium channel blocker; uniquely effective for bipolar depression and a first-line maintenance mood stabilizer.

    Abstract

    Lamotrigine (3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; CAS 84057-84-1; molecular formula C9H7Cl2N5; molecular weight 256.09) is a phenyltriazine voltage-gated sodium channel blocker developed at Wellcome (now GSK) and approved by the FDA in 1994 under the trade name Lamictal. Mechanism: state-dependent inhibition of voltage-gated sodium channels (preferentially binding inactivated state), reducing release of presynaptic glutamate and aspartate. Secondary inhibition of high-voltage-activated calcium channels and weak antagonism at 5-HT3 receptors contribute to the broader profile. Distinct among anticonvulsants for efficacy in bipolar depression and maintenance mood stabilization (more effective at preventing depressive than manic episodes, opposite the lithium pattern). Plasma half-life is 25 to 33 hours alone, shortened by enzyme-inducing comedications. Hepatic metabolism is primarily glucuronidation. The principal limitation is a benign rash incidence of approximately 10 percent and Stevens-Johnson syndrome at approximately 1 in 1000, both reduced by slow titration over 4 to 6 weeks. Approved for partial-onset seizures, primary generalized tonic-clonic seizures, Lennox-Gastaut syndrome, and bipolar I disorder maintenance. Used as the reference anticonvulsant mood stabilizer and as a clean voltage-gated sodium channel blocker.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.